Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871323 | 0.86 | KIF11 (0.49) | KIF11KIF23 | |
| SCHEMBL4039832 | 0.85 | KIF11 (0.48) | KIF11KIF23 | |
| SCHEMBL4039298 | 0.84 | KIF11 (0.54) | KIF11KIF23 | |
| SCHEMBL4039243 | 0.84 | KIF11 (0.53) | KIF11KIF23 | |
| SCHEMBL5899029 | 0.83 | KIF11 (0.47) | KIF11KIF23 | |
| SCHEMBL3867071 | 0.82 | KIF11 (0.59) | KIF11KIF23 | |
| Hydrochloric Acid SCHEMBL3873756 | 0.82 | KIF11 (0.59) | KIF11KIF23 | |
| SCHEMBL4046310 | 0.81 | KIF11 (0.53) | KIF11KIF23 | |
| SCHEMBL4036178 | 0.79 | KIF11 (0.46) | KIF11KIF23 | |
| SCHEMBL4060625 | 0.78 | KIF11 (0.41) | KIF11KIF23 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | KIF11 3171/4885KIF23 3405/4885 |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | BRCA1, CYP1B1, CCNI | KIF11 3559/4885KIF23 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.